Abstract
Pharmaceutical products continue to be developed for improved patient compliance, but the issue of hydrophobicity, low permeability, short half-life, and stability of various drugs always has been a challenging task for formulation development. Conventional formulations lack the features of prolong release of drug over an extended period of time and site-specific action. To resolve these issues, cyclodextrin has emerged as an exceptional pharmaceutical excipient with the features of bioavailability, nontoxicity, inclusion ability, and water solubility. Additionally, nanoparticles overcome the drawbacks associated with conventional formulations such as prolong release and site-specific action of active molecules. Cyclodextrins and chemically altered cyclodextrins in combination with certain polymers have sparked various researchers for exceptional advancements in the field of novel drug delivery. More recently, these substances have been incorporated in polymer systems to develop nanoparticles. Cyclodextrin conjugated nanoparticles offer synergistic advantages such as enhanced drug solubility, served as drug carriers to a specific target site such as cancer cells with minimum toxicity to normal cells, greater surface area over microparticles, and higher stability over liposomes. Accordingly, nanoparticles based on cyclodextrins have gained notable interest, and a variety of nanoparticles have been developed since the last two decades.
This chapter review major critical research on cyclodextrin-based nanoparticles to explain their versatility and high potential for advanced drug delivery, protein and peptide drug delivery, and gene delivery. This chapter also highlights the role of cyclodextrins in specific types of nanoparticles such as gold, silver, and magnetic, polymeric, and lipid-based nanoparticles. Finally, pharmaceutical applications of amphiphilic cyclodextrin nanoparticles and miscellaneous administration routes of cyclodextrin-based nanoparticles are also discussed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- DNA:
-
Deoxyribonucleic acid
- MCF-7:
-
Michigan Cancer Foundation-7
- MDR1:
-
Multidrug resistance protein 1
- mRNA:
-
Messenger ribonucleic acid
- RNA:
-
Ribonucleic acid
- siRNA:
-
Small interfering ribonucleic acid
References
Agüeros M, Ruiz-Gatón L, Vauthier C, Bouchemal K, Espuelas S, Ponchel G, Irache JM (2009) Combined hydroxypropyl-β-cyclodextrin and poly(anhydride) nanoparticles improve the oral permeability of paclitaxel. Eur J Pharm Sci 38:405–413. https://doi.org/10.1016/j.ejps.2009.09.010
Agüeros M, Espuelas S, Esparza I, Calleja P, Peñuelas I, Ponchel G, Irache JM (2011) Cyclodextrin-poly(anhydride) nanoparticles as new vehicles for oral drug delivery. Expert Opin Drug Deliv 8:721–734. https://doi.org/10.1517/17425247.2011.572069
Ahmed GHG, Laíño RB, Calzón JAG, García MED (2014) Magnetic nanoparticles grafted with β-cyclodextrin for solid-phase extraction of 5-hydroxy-3-indole acetic acid. Microchim Acta 181:941–948. https://doi.org/10.1007/s00604-014-1192-y
Ammar H, El-Nahhas S, Ghorab M, Salama A (2012) Chitosan/Cyclodextrin nanoparticles as drug delivery system. J Incl Phenom Macrocycl Chem 72:9950–9955. https://doi.org/10.1007/s10847-011
Anirudhan TS, Dilu D, Sandeep S (2013) Synthesis and characterisation of chitosan crosslinked-β-cyclodextrin grafted silylated magnetic nanoparticles for controlled release of Indomethacin. J Magn Magn Mater 343:149–156. https://doi.org/10.1016/j.jmmm.2013.04.007
Anirudhan TS, Divya PL, Nima J (2015) Synthesis and characterization of silane coated magnetic nanoparticles/glycidylmethacrylate-grafted-maleated cyclodextrin composite hydrogel as a drug carrier for the controlled delivery of 5-fluorouracil. Mater Sci Eng C 55:471–481. https://doi.org/10.1016/j.msec.2015.05.068
Aranda C, Urbiola K, Méndez Ardoy A, García Fernández JM, Ortiz Mellet C, de Ilarduya CT (2013) Targeted gene delivery by new folate-polycationic amphiphilic cyclodextrin-DNA nanocomplexes in vitro and in vivo. Eur J Pharm Biopharm 85:390–397. https://doi.org/10.1016/j.ejpb.2013.06.011
Arima H, Hagiwara Y, Hirayama F, Uekama K (2006) Enhancement of antitumor effect of doxorubicin by its complexation with γ-cyclodextrin in pegylated liposomes. J Drug Target 14:225–232. https://doi.org/10.1080/10611860600711136
Ascenso A, Cruz M, Euletério C, Carvalho FA, Santos NC, Marques HC, Simões S (2013) Novel tretinoin formulations: a drug-in-cyclodextrin-in-liposome approach. J Liposome Res 23:211–219. https://doi.org/10.3109/08982104.2013.788026
Badruddoza AZM, Rahman MT, Ghosh S, Hossain MZ, Shi J, Hidajat K, Uddin MS (2013) β-Cyclodextrin conjugated magnetic, fluorescent silica core-shell nanoparticles for biomedical applications. Carbohydr Polym 95:449–457. https://doi.org/10.1016/j.carbpol.2013.02.046
Baek JS, Cho CW (2013) 2-Hydroxypropyl-β-cyclodextrin-modified SLN of paclitaxel for overcoming p-glycoprotein function in multidrug-resistant breast cancer cells. J Pharm Pharmacol 65:72–78. https://doi.org/10.1111/j.2042-7158.2012.01578.x
Baek JS, Kim JH, Park JS, Cho CW (2015) Modification of paclitaxel-loaded solid lipid nanoparticles with 2-hydroxypropyl-β-cyclodextrin enhances absorption and reduces nephrotoxicity associated with intravenous injection. Int J Nanomedicine 10:5397–5405. https://doi.org/10.2147/IJN.S86474
Bakar F, Caglayan M, Onur F, Nebioglu S, Palabiyik I (2015) Gold nanoparticle-lignan complexes inhibited MCF-7 cell proliferation in vitro: a novel conjugation for cancer therapy. Anticancer Agents Med Chem 15:336–344. https://doi.org/10.2174/1871520614666141202144152
Banerjee SS, Chen DH (2007) Magnetic nanoparticles grafted with cyclodextrin for hydrophobic drug delivery. Chem Mater 19:6345–6349. https://doi.org/10.1021/cm702278u
Bilensoy E, Hincal AA (2009) Recent advances and future directions in amphiphilic cyclodextrin nanoparticles. Expert Opin Drug Deliv 6:1161–1173. https://doi.org/10.1517/17425240903222218
Bilensoy E, Gürkaynak O, Doǧan AL, Hincal AA (2008a) Safety and efficacy of amphiphilic ß-cyclodextrin nanoparticles for paclitaxel delivery. Int J Pharm 347:163–170. https://doi.org/10.1016/j.ijpharm.2007.06.051
Bilensoy E, Gürkaynak O, Ertan M, Şen M, Hincal AA (2008b) Development of nonsurfactant cyclodextrin nanoparticles loaded with anticancer drug paclitaxel. J Pharm Sci 97:1519–1529. https://doi.org/10.1002/jps.21111
Bragagni M, Maestrelli F, Mura P (2010) Physical chemical characterization of binary systems of prilocaine hydrochloride with triacetyl-β-cyclodextrin. J Incl Phenom Macrocycl Chem 68:437–445. https://doi.org/10.1007/s10847-010-9807-3
Bu X, Zhu T, Ma Y, Shen Q (2015) Co-administration with cell penetrating peptide enhances the oral bioavailability of docetaxel-loaded nanoparticles. Drug Dev Ind Pharm 41:764–771. https://doi.org/10.3109/03639045.2014.902465
Campos EVR, Proença PLF, Oliveira JL, Melville CC, Vechia JFD, De Andrade DJ, Fraceto LF (2018) Chitosan nanoparticles functionalized with β-cyclodextrin: a promising carrier for botanical pesticides. Sci Rep 8. https://doi.org/10.1038/s41598-018-20602-y
Carlotti M, Sapino S, Ugazio E, Gallarate M, Morel S (2012) Resveratrol in solid lipid nanoparticles. J Dispers Sci Technol 33:465–471. https://doi.org/10.1080/01932691.2010.548274
Cavalcanti IMF, Mendona EAM, Lira MCB, Honrato SB, Camara CA, Amorim RVS, Filho JM, Rabello MM, Hernandes MZ, Ayala AP, Santos-Magalhães NS (2011) The encapsulation of β-lapachone in 2-hydroxypropyl-β-cyclodextrin inclusion complex into liposomes: a physicochemical evaluation and molecular modeling approach. Eur J Pharm Sci 44:332–340. https://doi.org/10.1016/j.ejps.2011.08.011
Cavalli R, Peira E, Caputo O, Gasco MR (1999) Solid lipid nanoparticles as carriers of hydrocortisone and progesterone complexes with β-cyclodextrins. Int J Pharm 182:59–69. https://doi.org/10.1016/S0378-5173(99)00066-6
Cavalli R, Trotta F, Carlotti ME, Possetti B, Trotta M (2007) Nanoparticles derived from amphiphilic-γ-cyclodextrins. J Incl Phenom Macrocycl Chem 57:657–661. https://doi.org/10.1007/s10847-006-9269-9
Challa R, Ahuja A, Ali J, Khar RK (2005) Cyclodextrins in drug delivery: an updated review. AAPS Pharm SciTech 6:2. https://doi.org/10.1208/pt060243
Chen H, Gao J, Wang F, Wenquan L (2007) Preparation, characterization and pharmacokinetics of liposomes-encapsulated cyclodextrins inclusion complexes for hydrophobic drugs. Drug Deliv 14:201–208. https://doi.org/10.1080/10717540601036880
Chen P, Song H, Yao S, Tu X, Su M, Zhou L (2017) Magnetic targeted nanoparticles based on β-cyclodextrin and chitosan for hydrophobic drug delivery and a study of their mechanism. RSC Adv 7:29025–29034. https://doi.org/10.1039/C7RA02398G
Chen P, Yao S, Chen X, Huang Y, Song H (2019) A new strategy for the construction of β-cyclodextrin-based magnetic nanocarriers: a molecular docking technique. New J Chem 43:4282–4290. https://doi.org/10.1039/c8nj06131a
Chirio D, Gallarate M, Peira E, Battaglia L, Serpe L, Trotta M (2011) Formulation of curcumin-loaded solid lipid nanoparticles produced by fatty acids coacervation technique. J Microencapsul 28:537–548. https://doi.org/10.3109/02652048.2011.590615
Çirpanli Y, Bilensoy E, Lale Doǧan A, Çaliş S (2009) Comparative evaluation of polymeric and amphiphilic cyclodextrin nanoparticles for effective camptothecin delivery. Eur J Pharm Biopharm 73:82–89. https://doi.org/10.1016/j.ejpb.2009.04.013
Çirpanli Y, Allard E, Passirani C, Bilensoy E, Lemaire L, Caliş S, Benoit JP (2011) Antitumoral activity of camptothecin-loaded nanoparticles in 9L rat glioma model. Int J Pharm 17:201–206. https://doi.org/10.1016/j.ijpharm.2010.10.015
Cirri M, Bragagni M, Mennini N, Mura P (2012) Development of a new delivery system consisting in “drug – In cyclodextrin – In nanostructured lipid carriers” for ketoprofen topical delivery. Eur J Pharm Biopharm 80:46–53. https://doi.org/10.1016/j.ejpb.2011.07.015
Cirri M, Mennini N, Maestrelli F, Mura P, Ghelardini Cyclodextrini Cesare Mannelli L (2017) Development and in vivo evaluation of an innovative “hydrochlorothiazide-in cyclodextrins-in solid lipid nanoparticles” formulation with sustained release and enhanced oral bioavailability for potential hypertension treatment in pediatrics. Int J Pharm 521:73–83. https://doi.org/10.1016/j.ijpharm.2017.02.022
Cirri M, Maestrelli F, Mura P, Ghelardini C, Mannelli LDC (2018) Combined approach of cyclodextrin complexation and nanostructured lipid carriers for the development of a pediatric liquid oral dosage form of hydrochlorothiazide. Pharmaceutics 10:287. https://doi.org/10.3390/pharmaceutics10040287
Conte C, Costabile G, d’Angelo I, Pannico M, Musto P, Grassia G, Ialenti A, Tirino P, Miro A, Ungaro F, Quaglia F (2015) Skin transport of PEGylated poly(ε-caprolactone) nanoparticles assisted by (2-hydroxypropyl)-β-cyclodextrin. J Colloid Interface Sci 454:112–120. https://doi.org/10.1016/j.jcis.2015.05.010
Crini G (2014) Review: a history of cyclodextrins. Chem Rev 114:10940–10975. https://doi.org/10.1021/cr500081p
Da Silveira AM, Ponchel G, Puisieux F, Duchêne D (1998) Combined poly(isobutylcyanoacrylate) and cyclodextrins nanoparticles for enhancing the encapsulation of lipophilic drugs. Pharm Res 15:1051–1055. https://doi.org/10.1023/A:1011982211632
Datz S, Illes B, Gößl D, Schirnding CV, Engelke H, Bein T (2018) Biocompatible crosslinked β-cyclodextrin nanoparticles as multifunctional carriers for cellular delivery. Nanoscale 10:16284–16292. https://doi.org/10.1039/c8nr02462f
Dhule SS, Penfornis P, Frazier T, Walker R, Feldman J, Tan G, He J, Alb A, John V, Pochampally R (2012) Curcumin-loaded γ-cyclodextrin liposomal nanoparticles as delivery vehicles for osteosarcoma. Nanomedicine 8:440–451. https://doi.org/10.1016/j.nano.2011.07.011
Díaz-Moscoso A, Guilloteau N, Bienvenu C, Méndez-Ardoy A, Jiménez Blanco J, Benito J, Gourriérec L, Di Giorgio C, Vierling P, Defaye J, Mellet C, García Fernández J (2011) Mannosyl-coated nanocomplexes from amphiphilic cyclodextrins and pDNA for site-specific gene delivery. Biomaterials 32:7263–7273. https://doi.org/10.1016/j.biomaterials.2011.06.025
Ding Y, Shen SZ, Sun H, Sun K, Liu F, Qi Y, Yan J (2015) Design and construction of polymerized-chitosan coated Fe3O4 magnetic nanoparticles and its application for hydrophobic drug delivery. Mater Sci Eng C 48:487–498. https://doi.org/10.1016/j.msec.2014.12.036
Donohue R, Mazzaglia A, Ravoo BJ, Darcy R (2002) Cationic β-cyclodextrin bilayer vesicles. Chem Commun 2:2864–2865. https://doi.org/10.1039/b207238f
Dubes A, Parrot-Lopez H, Abdelwahed W, Degobert G, Fessi H, Shahgaldian P, Coleman AW (2003) Scanning electron microscopy and atomic force microscopy imaging of solid lipid nanoparticles derived from amphiphilic cyclodextrins. Eur J Pharm Biopharm 55:279–282. https://doi.org/10.1016/S0939-6411(03)00020-1
Duchêne D, Ponchel G, Wouessidjewe D (1999a) Cyclodextrins in targeting application to nanoparticles. Adv Drug Deliv Rev 36:29–40. https://doi.org/10.1016/S0169-409X(98)00053-2
Duchêne D, Wouessidjewe D, Ponchel G (1999b) Cyclodextrins and carrier systems. J Control Release 62:263–268. https://doi.org/10.1016/S0168-3659(99)00046-2
El Fagui A, Dalmas F, Lorthioir C, Wintgens V, Volet G, Amiel C (2011) Well-defined core-shell nanoparticles containing cyclodextrin in the shell: a comprehensive study. Polymer 52:3752–3761. https://doi.org/10.1016/j.polymer.2011.06.043
Enoch IVMV, Ramasamy S, Mohiyuddin S, Gopinath P (2018) Cyclodextrin-PEG conjugate-wrapped magnetic ferrite nanoparticles for enhanced drug loading and release. Appl Nanosci 8:273–284. https://doi.org/10.1007/s13204-018-0798-5
Erdogar N, Varan G, Bilensoy E (2017) Amphiphilic cyclodextrin derivatives for targeted drug delivery to tumors. Curr Top Med Chem 17:1521–1528. https://doi.org/10.2174/1568026616666161222101104
Evans J, Malhotra M, Fitzgerald K, Guo J, Cronin M, Curtin C, O’Brien F, Darcy R, O’Driscoll C (2017) Formulation and evaluation of anisamide-targeted amphiphilic cyclodextrin nanoparticles to promote therapeutic gene silencing in a 3d prostate cancer bone metastases model. Mol Pharm 3:42–52. https://doi.org/10.1021/acs.molpharmaceut.6b00646
Fatouros DG, Hatzidimitriou K, Antimisiaris SG (2001) Liposomes encapsulating prednisolone and prednisolone-cyclodextrin complexes: comparison of membrane integrity and drug release. Eur J Pharm Sci 13:287–296. https://doi.org/10.1016/S0928-0987(01)00114-2
Gannimani R, Ramesh M, Mtambo S, Pillay K, Soliman ME, Govender P (2016) γ-Cyclodextrin capped silver nanoparticles for molecular recognition and enhancement of antibacterial activity of chloramphenicol. J Inorg Biochem 157:15–24. https://doi.org/10.1016/j.jinorgbio.2016.01.008
Gao H, Wang YN, Fan YG, Ma JB (2005) Synthesis of a biodegradable tadpole-shaped polymer via the coupling reaction of polylactide onto mono(6-(2-aminoethyl)amino-6-deoxy)-β- cyclodextrin and its properties as the new carrier of protein delivery system. J Control Release 107:158–173. https://doi.org/10.1016/j.jconrel.2005.06.010
Gao J, Ma H, Lv X, Yan T, Li N, Cao W, Wei Q (2015) A novel electrochemical immunosensor using β-cyclodextrins functionalized silver supported adamantine-modified glucose oxidase as labels for ultrasensitive detection of alpha-fetoprotein. Anal Chim Acta 893:49–56. https://doi.org/10.1016/j.aca.2015.08.052
García-González L, Yépez-Mulía L, Ganem A (2016) Effect of β-cyclodextrin on the internalization of nanoparticles into intestine epithelial cells. Eur J Pharm Sci 81:113–118. https://doi.org/10.1016/j.ejps.2015.10.012
Gaurav C, Nikhil G, Deepti S, Kalra S, Goutam R, Amit GK (2015) Albumin stabilized silver nanoparticles-clotrimazole β-cyclodextrin hybrid nanocomposite for enriched anti-fungal activity in normal and drug resistant Candida cells. RSC Adv 5:71190–71202. https://doi.org/10.1039/c5ra08274a
George C, Kuriakose S, George S, Mathew T (2011) Antifungal activity of silver nanoparticle-encapsulated β-cyclodextrin against human opportunistic pathogens. Supramol Chem 23:593–597. https://doi.org/10.1080/10610278.2011.575471
Gèze A, Chau LT, Choisnard L, Mathieu JP, Marti-Batlle D, Riou L, Putaux JL, Wouessidjewe D (2007) Biodistribution of intravenously administered amphiphilic β-cyclodextrin nanospheres. Int J Pharm 344:135–142. https://doi.org/10.1016/j.ijpharm.2007.06.050
Ghera BB, Perret F, Chevalier Y, Parrot-Lopez H (2009) Novel nanoparticles made from amphiphilic perfluoroalkyl alpha-cyclodextrin derivatives: preparation, characterization and application to the transport of acyclovir. Int J Pharm 22:155–162. https://doi.org/10.1016/j.ijpharm.2009.04.004
Gil ES, Li J, Xiao H, Lowe TL (2009) Quaternary ammonium β-cyclodextrin nanoparticles for enhancing doxorubicin permeability across the in vitro blood-brain barrier. Biomacromolecules 10:505–516. https://doi.org/10.1021/bm801026k
Godinho BMDC, Ogier JR, Darcy R, O’Driscoll CM, Cryan JF (2013) Self-assembling modified β-cyclodextrin nanoparticles as neuronal siRNA delivery vectors: focus on Huntington’s disease. Mol Pharm 10:640–649. https://doi.org/10.1021/mp3003946
Godinho BMDC, Ogier JR, Quinlan A, Darcy R, Griffin BT, Cryan JF, Caitriona MOD (2014) PEGylated cyclodextrins as novel siRNA nanosystems: correlations between polyethylene glycol length and nanoparticle stability. Int J Pharm 473:105–112. https://doi.org/10.1016/j.ijpharm.2014.06.054
Gonzalez H, Hwang SJ, Davis ME (1999) New class of polymers for the delivery of macromolecular therapeutics. Bioconjug Chem 10:1068–1074. https://doi.org/10.1021/bc990072j
Gooding M, Malhotra M, McCarthy DJ, Godinho BMDC, Cryan JF, Darcy R, O’Driscoll CM (2015) Synthesis and characterization of rabies virus glycoprotein-tagged amphiphilic cyclodextrins for siRNA delivery in human glioblastoma cells: in vitro analysis. Eur J Pharm Sci 71:80–92. https://doi.org/10.1016/j.ejps.2015.02.007
Gorjikhah F, Azizi Jalalian F, Salehi R, Panahi Y, Hasanzadeh A, Alizadeh E, Akbarzadeh A, Davaran S (2017) Preparation and characterization of PLGA-β-cyclodextrin polymeric nanoparticles containing methotrexate and evaluation of their effects on T47D cell line. Artif Cells Nanomed Biotechnol 45:432–440. https://doi.org/10.3109/21691401.2016.1160915
Guo J, Ogier JR, Desgranges S, Darcy R, ODriscoll C (2012) Anisamide-targeted cyclodextrin nanoparticles for siRNA delivery to prostate tumours in mice. Biomaterials 33:7775–7784. https://doi.org/10.1016/j.biomaterials.2012.07.012
Guo B, Xu D, Liu X, Liao C, Li S, Huang Z, Li X, Yi J (2017) Characterization and cytotoxicity of PLGA nanoparticles loaded with formononetin cyclodextrin complex. J Drug Delivery Sci Technol 41:375–383. https://doi.org/10.1016/j.jddst.2017.08.010
Ha W, Kang Y, Peng SL, Ding LS, Zhang S, Li BJ (2013) Vesicular gold assemblies based on host-guest inclusion and its controllable release of doxorubicin. Nanotechnology 24. https://doi.org/10.1088/0957-4484/24/49/495103
Hamada H, Ishihara K, Masuoka N, Mikuni K, Nakajima N (2006) Enhancement of water-solubility and bioactivity of paclitaxel using modified cyclodextrins. J Biosci Bioeng 102:369–371. https://doi.org/10.1263/jbb.102.369
He M, Zhong C, Hu H, Jin Y, Chen Y, Lou K, Gao F (2019) Cyclodextrin/chitosan nanoparticles for oral ovalbumin delivery: preparation, characterization and intestinal mucosal immunity in mice. Asian J Pharm Sci 14:193–203. https://doi.org/10.1016/j.ajps.2018.04.001
Hippalgaonkar K, Adelli GR, Hippalgaonkar K, Repka MA, Majumdar S (2013) Indomethacin-loaded solid lipid nanoparticles for ocular delivery: development, characterization, and in vitro evaluation. J Ocul Pharmacol Ther 29:216–228. https://doi.org/10.1089/jop.2012.006
Holzinger M, Bouffier L, Villalonga R, Cosnier S (2009) Adamantane/β-cyclodextrin affinity biosensors based on single-walled carbon nanotubes. Biosens Bioelectron 24:1128–1134. https://doi.org/10.1016/j.bios.2008.06.029
Hou X, Zhang W, He M, Lu Y, Lou K, Gao F (2017) Preparation and characterization of β-cyclodextrin grafted N-maleoyl chitosan nanoparticles for drug delivery. Asian J Pharm Sci 12:558–568. https://doi.org/10.1016/j.ajps.2017.07.007
Hui Y, Ma X, Hou X, Chen F, Yu J (2015) Silver nanoparticles-β-cyclodextrin-graphene nanocomposites based biosensor for guanine and adenine sensing. Ionics (Kiel) 21:1751–1759. https://doi.org/10.1007/s11581-014-1343-5
Irie T, Uekama K (1997) Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J Pharm Sci 86:147–162. https://doi.org/10.1021/js960213f
Jain SK, Gupta Y, Jain A, Bhola M (2007) Multivesicular liposomes bearing celecoxib-β-cyclodextrin complex for transdermal delivery. Drug Deliv 14:327–335. https://doi.org/10.1080/10717540601098740
Jaiswal S, Bhattacharya K, McHale P, Duffy B (2015) Dual effects of β-cyclodextrin-stabilised silver nanoparticles: enhanced biofilm inhibition and reduced cytotoxicity. J Mater Sci Mater Med 26. https://doi.org/10.1007/s10856-014-5367-1
Ji T, Li S, Zhang Y, Lang J, Ding Y, Zhao X, Zhao R, Li Y, Shi J, Hao J, Zhao Y, Nie G (2016) An MMP-2 responsive liposome integrating antifibrosis and chemotherapeutic cyclodextrin drugs for enhanced drug perfusion and efficacy in pancreatic cancer. ACS Appl Mater Interfaces 8:3438–3445. https://doi.org/10.1021/acsami.5b11619
Kadari A, Gudem S, Kulhari H, Bhandi MM, Borkar RM, Kolapalli VRM, Sistla R (2017) Enhanced oral bioavailability and anticancer efficacy of fisetin by encapsulating as inclusion complex with HPβCD in polymeric nanoparticles. Drug Deliv 24:224–232. https://doi.org/10.1080/10717544.2016.1245366
Khalil SK, El-Feky GS, El-Banna ST, Khalil WA (2012) Preparation and evaluation of warfarin-β-cyclodextrin loaded chitosan nanoparticles for transdermal delivery. Carbohydr Polym 15:1244–1253. https://doi.org/10.1016/j.carbpol.2012.06.056
Krauland AH, Alonso MJ (2007) Chitosan/cyclodextrin nanoparticles as macromolecular drug delivery system. Int J Pharm 340:134–142. https://doi.org/10.1016/j.ijpharm.2007.03.005
Kurkov SV, Loftsson T (2013) Cyclodextrins. Int J Pharm 30:167–180. https://doi.org/10.1016/j.ijpharm.2012.06.055
Kwon TK, Kim JC (2010) In vitro skin permeation of mono olein nanoparticles containing hydroxypropyl beta-cyclodextrin/minoxidil complex. Int J Pharm 392:268–273. https://doi.org/10.1016/j.ijpharm.2010.03.04
Langie SAS, Knaapen AM, Houben JMJ, van Kempen FC, de Hoon JPJ, Gottschalk RWH, Godschalk RWL, van Schooten FJ (2007) The role of glutathione in the regulation of nucleotide excision repair during oxidative stress. Toxicol Lett 168:302–309. https://doi.org/10.1016/j.toxlet.2006.10.027
Li R, Liu S, Zhao J, Otsuka H, Takahara A (2011) Preparation of superparamagnetic β-cyclodextrin-functionalized composite nanoparticles with core-shell structures. Polym Bull 66:1125–1136. https://doi.org/10.1007/s00289-010-0410-y
Lin C, Chen F, Ye T, Zhang L, Zhang W, Liu D, Xiong W, Yang X, Pan W (2014) A novel oral delivery system consisting in “drug-in cyclodextrin-in nanostructured lipid carriers” for poorly water-soluble drug: Vinpocetine. Int J Pharm 465:90–96. https://doi.org/10.1016/j.ijpharm.2014.02.013
Liu J, Xu R, Kaifer AE (1998) In situ modification of the surface of gold colloidal particles. Preparation of cyclodextrin-based rotaxanes supported on gold nanospheres. Langmuir 14:7337–7339. https://doi.org/10.1021/la981385q
Loftsson T, Duchêne D (2007) Cyclodextrins and their pharmaceutical applications. Int J Pharm 329:1–11. https://doi.org/10.1016/j.ijpharm.2006.10.044
Luo Z, Cai K, Hu Y, Li J, Ding X, Zhang B, Xu D, Yang W, Liu P (2012) Redox-responsive molecular nanoreservoirs for controlled intracellular anticancer drug delivery based on magnetic nanoparticles. Adv Mater 24:431–435. https://doi.org/10.1002/adma.201103458
Luppi B, Bigucci F, Corace G, Delucca A, Cerchiara T, Sorrenti M, Catenacci L, Di Pietra AM, Zecchi V (2011) Albumin nanoparticles carrying cyclodextrins for nasal delivery of the anti-Alzheimer drug tacrine. Eur J Pharm Sci 44:559–565. https://doi.org/10.1016/j.ejps.2011.10.002
Lysik MA, Wu-Pong S (2003) Innovations in oligonucleotide drug delivery. J Pharm Sci 92:1559–1573. https://doi.org/10.1002/jps.10399
Mady FM, Abou-Taleb AE, Khaled KA, Yamasaki K, Iohara D, Taguchi K, Anraku M, Hirayama F, Uekama K, Otagiri M (2010) Evaluation of carboxymethyl-β-cyclodextrin with acid function: improvement of chemical stability, oral bioavailability and bitter taste of famotidine. Int J Pharm 397:1–8. https://doi.org/10.1016/j.ijpharm.2010.06.018
Maestrelli F, González-Rodríguez ML, Rabasco AM, Mura P (2005) Preparation and characterisation of liposomes encapsulating ketoprofen-cyclodextrin complexes for transdermal drug delivery. Int J Pharm 298:55–67. https://doi.org/10.1016/j.ijpharm.2005.03.033
Maestrelli F, Garcia-Fuentes M, Mura P, Alonso MJ (2006) A new drug nanocarrier consisting of chitosan and hydroxyl propyl cyclodextrin. Eur J Pharm Biopharm 63:79–86. https://doi.org/10.1016/j.ejpb.2005.12.006
Maestrelli F, González-Rodríguez ML, Rabasco AM, Ghelardini C, Mura P (2010) New “drug-in cyclodextrin-in deformable liposomes” formulations to improve the therapeutic efficacy of local anaesthetics. Int J Pharm 395:222–231. https://doi.org/10.1016/j.ijpharm.2010.05.046
Mahmoud AA, El-Feky GS, Kamel R, Awad GEA (2011) Chitosan/sulfobutylether-β-cyclodextrin nanoparticles as a potential approach for ocular drug delivery. Int J Pharm 413:229–236. https://doi.org/10.1016/j.ijpharm.2011.04.031
McCormack B, Gregoriadis G (1994a) Drugs-in-cyclodextrins-in liposomes: a novel concept in drug delivery. Int J Pharm 112:249–258. https://doi.org/10.1016/0378-5173(94)90361-1
McCormack B, Gregoriadis G (1994b) Entrapment of cyclodextrin-drug complexes into liposomes: potential advantages in drug delivery. J Drug Target 2:449–454. https://doi.org/10.3109/10611869408996821
McCormack B, Gregoriadis G (1996) Comparative studies of the fate of free and liposome-entrapped hydroxypropyl-β-cyclodextrin/drug complexes after intravenous injection into rats: implications in drug delivery. Biochim Biophys Acta 1291:237–244. https://doi.org/10.1016/S0304-4165(96)00096-7
Memişoğlu E, Bochot A, Özalp M, Sen M, Duchêne D, Hincal A (2003) Direct formation of nanospheres from amphiphilic beta-cyclodextrin inclusion complexes. Pharm Res 20:117–125. https://doi.org/10.1023/A:1022263111961
Bilensoy E, Vural I, Bochot A, Renoir JM, Duchene D, Hincal AA (2005) Tamoxifen citrate loaded amphiphilic β-cyclodextrin nanoparticles: in vitro characterization and cytotoxicity. J Control Release 104:489–496. https://doi.org/10.1016/j.jconrel.2005.03.006
Méndez-Ardoy A, Guilloteau N, Di Giorgio C, Vierling P, Santoyo-González F, Ortiz Mellet C, García Fernández JM (2011) β-cyclodextrin-based polycationic amphiphilic “click” clusters: effect of structural modifications in their DNA complexing and delivery properties. J Org Chem 76:5882–5894. https://doi.org/10.1021/jo2007785
Mennini N, Cirri M, Maestrelli F, Mura P (2016) Comparison of liposomal and NLC (nanostructured lipid carrier) formulations for improving the transdermal delivery of oxaprozin: effect of cyclodextrin complexation. Int J Pharm 515:684–691. https://doi.org/10.1016/j.ijpharm.2016.11.013
Merkus FWHM, Verhoef JC, Romeijn SG, Schipper NGM (1991) Absorption enhancing effect of cyclodextrins on intranasally administered insulin in rats. Pharm Res 8:588–592. https://doi.org/10.1023/A:1015896405389
Merkus FWHM, Verhoef JC, Marttin E, Romeijn SG, Van Der Kuy PHM, Hermens WAJJ, Schipper NGM (1999) Cyclodextrins in nasal drug delivery. Adv Drug Deliv Rev 36:41–57. https://doi.org/10.1016/S0169-409X(98)00054-4
Messner M, Kurkov SV, Jansook P, Loftsson T (2010) Self-assembled cyclodextrin aggregates and nanoparticles. Int J Pharm 387:199–208. https://doi.org/10.1016/j.ijpharm.2009.11.035
Mrówczyński R, Jędrzak A, Szutkowski K, Grześkowiak BF, Coy E, Markiewicz R, Jesionowski T, Jurga S (2018) Cyclodextrin-based magnetic nanoparticles for cancer therapy. Nanomaterials (Basel) 8:170. https://doi.org/10.3390/nano8030170
Mura P, Maestrelli F, Cecchi M, Bragagni M, Almeida A (2010) Development of a new delivery system consisting in drug in cyclodextrin in PLGA nanoparticles. J Microencapsul 27:479–486. https://doi.org/10.3109/02652040903515508
Negi JS, Chattopadhyay P, Sharma AK, Ram V (2014) Preparation of gamma cyclodextrin stabilized solid lipid nanoparticles (SLNS) using stearic acid-γ-cyclodextrin inclusion complex. J Incl Phenom Macrocycl Chem 80:359–368. https://doi.org/10.1007/s10847-014-0415-5
Nguyen HT, Goycoolea FM (2017) Chitosan/Cyclodextrin/TPP nanoparticles loaded with quercetin as novel bacterial quorum sensing inhibitors. Molecules 22:1975. https://doi.org/10.3390/molecules22111975
Park IK, Von Recum HA, Jiang S, Pun SH (2006) Supramolecular assembly of cyclodextrin-based nanoparticles on solid surfaces for gene delivery. Langmuir 22:8478–8484. https://doi.org/10.1021/la061757s
Piel G, Piette M, Barillaro V, Castagne D, Evrard B, Delattre L (2006) Betamethasone-in-cyclodextrin-in-liposome: the effect of cyclodextrins on encapsulation efficiency and release kinetics. Int J Pharm 312:75–82. https://doi.org/10.1016/j.ijpharm.2005.12.044
Ping Y, Liu C, Zhang Z, Liu KL, Chen J, Li J (2011) Chitosan-graft-(PEI-β-cyclodextrin) copolymers and their supramolecular PEGylation for DNA and siRNA delivery. Biomaterials 32:8328–8341. https://doi.org/10.1016/j.biomaterials.2011.07.038
Pires FQ, da Silva JKR, Sa-Barreto LL, Gratieri T, Gelfuso GM, Cunha-Filho M (2019) Lipid nanoparticles as carriers of cyclodextrin inclusion complexes: a promising approach for cutaneous delivery of a volatile essential oil. Colloids Surf B Biointerfaces 182:110382. https://doi.org/10.1016/j.colsurfb.2019.110382
Prabha G, Raj V (2016) Formation and characterization of β-cyclodextrin (β-cyclodextrin) – polyethyleneglycol (PEG)-polyethyleneimine (PEI) coated Fe3O4 nanoparticles for loading and releasing 5-fluorouracil drug. Biomed Pharmacother 80:173–182. https://doi.org/10.1016/j.biopha.2016.03.015
Prandina A, Herfindal L, Radix S, Rongved P, Døskeland SO, Le Borgne M, Perret F (2018) Enhancement of iodinin solubility by encapsulation into cyclodextrin nanoparticles. J Enzyme Inhib Med Chem 33:370–375. https://doi.org/10.1080/14756366.2017.1421638
Quaglia F, Ostacolo L, Mazzaglia A, Villari V, Zaccaria D, Sciortino MT (2009) The intracellular effects of non-ionic amphiphilic cyclodextrin nanoparticles in the delivery of anticancer drugs. Biomaterials 30:374–382. https://doi.org/10.1016/j.biomaterials.2008.09.035
Ren S, Chen D, Jiang M (2009) Noncovalently connected micelles based on a β-cyclodextrin-containing polymer and adamantane end-capped poly(ε-caprolactone) via host-guest interactions. J Polym Sci Part A Polym Chem 47:4267–4278. https://doi.org/10.1002/pola.23479
Sajeesh S, Sharma CP (2006) Cyclodextrin-insulin complex encapsulated polymethacrylic acid based nanoparticles for oral insulin delivery. Int J Pharm 325:147–154. https://doi.org/10.1016/j.ijpharm.2006.06.019
Schardinger F (1903) Uber die Zulässigkeit des Warmhaltens von zum Gebuß bestimmten Nahrungsmittel mittelst Wärme speichernder Apparate, sog. Thermophore Wien K lin Wochenschr:468–474
Sierpe R, Lang E, Jara P, Guerrero AR, Chornik B, Kogan MJ, Yutronic N (2015) Gold nanoparticles interacting with β-cyclodextrin-phenylethylamine inclusion complex: a ternary system for photothermal drug release. ACS Appl Mater Interfaces 7:15177–15181. https://doi.org/10.1021/acsami.5b00186
Škalko N, Brandl M, Bećirević-Laćan M, Filipović-Grčić J, Jalšenjak I (1996) Liposomes with nifedipine and nifedipine-cyclodextrin complex: calorimetrical and plasma stability comparison. Eur J Pharm Sci 4:359–366. https://doi.org/10.1016/S0928-0987(96)00180-7
Skiba M, Wouessidjewe D, Coleman A, Fessi H, Devissaguet JP, Duchene D, Puisieux F (1993) Preparation and use of novel cyclodextrin-based dispersible colloidal systems in the form of nanospheres. PCT Int Appl 23 pp. PCT Applications FR 93/00594 (Publication No. WO 93/25195)
Skiba M, Duchêne D, Puisieux F, Wouessidjewe D (1996) Development of a new colloidal drug carrier from chemically modified cyclodextrins: nanospheres and influence of physicochemical and technological factors on particle size. Int J Pharm 129:113–121. https://doi.org/10.1016/0378-5173(95)04272-5
Spada G, Gavini E, Cossu M, Rassu G, Giunchedi P (2012) Solid lipid nanoparticles with and without hydroxypropyl β-cyclodextrin: a comparative study of nanoparticles designed for colonic drug delivery. Nanotechnology:23. https://doi.org/10.1088/0957-4484/23/9/095101
Szente L, Szejtli J (1999) Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development. Adv Drug Deliv Rev 36:17–28. https://doi.org/10.1016/S0169-409X(98)00092-1
Tao HQ, Meng Q, Li MH, Yu H, Liu MF, Du D, Sun SL, Yang HC, Wang YM, Ye W, Yang LZ, Zhu DL, Jiang CL, Peng HS (2013) HP-β-cyclodextrin-PLGA nanoparticles improve the penetration and bioavailability of puerarin and enhance the therapeutic effects on brain ischemia-reperfusion injury in rats. Naunyn Schmiedeberg’s Arch Pharmacol 386:61–70. https://doi.org/10.1007/s00210-012-0804-5
Teijeiro-Osorio D, Remuñán-López C, Alonso MJ (2009) Chitosan/cyclodextrin nanoparticles can efficiently transfect the airway epithelium in vitro. Eur J Pharm Biopharm 71:257–263. https://doi.org/10.1016/J.EJPB.2008.09.020
Trapani A, Garcia-Fuentes M, Alonso MJ (2008) Novel drug nanocarriers combining hydrophilic cyclodextrins and chitosan. Nanotechnology 19. https://doi.org/10.1088/0957-4484/19/18/185101
Trapani A, Sitterberg J, Bakowsky U, Kissel T (2009) The potential of glycol chitosan nanoparticles as carrier for low water soluble drugs. Int J Pharm 375:97–106. https://doi.org/10.1016/j.ijpharm.2009.03.041
Trapani A, Lopedota A, Franco M, Cioffi N, Ieva E, Garcia-Fuentes M, Alonso MJ (2010) A comparative study of chitosan and chitosan/cyclodextrin nanoparticles as potential carriers for the oral delivery of small peptides. Eur J Pharm Biopharm 75:26–32. https://doi.org/10.1016/j.ejpb.2010.01.010
Vaidya B, Parvathaneni V, Kulkarni NS, Shukla SK, Damon JK, Sarode A, Kanabar D, Garcia JV, Mitragotri S, Muth A, Gupta V (2019) Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer. Int J Biol Macromol 122:338–347. https://doi.org/10.1016/j.ijbiomac.2018.10.181
Vakhariya RR, Talokar SS, Salunkhe VR, Magdum CS (2017) Formulation development and optimization of simvastatin loaded solid lipid nanoparticles. Asian J Res Pharm Sci 7:49. https://doi.org/10.5958/2231-5659.2017.00008.x
Varan G, Öncül S, Ercan A, Benito JM, Ortiz Mellet C, Bilensoy E (2016) Cholesterol-targeted anticancer and apoptotic effects of anionic and polycationic amphiphilic cyclodextrin nanoparticles. J Pharm Sci 105:3172–3182. https://doi.org/10.1016/j.xphs.2016.06.021
Varan G, Patrulea V, Borchard G, Bilensoy E (2018) Cellular interaction and tumoral penetration properties of cyclodextrin nanoparticles on 3D breast tumor model. Nanomaterials 8:1–18. https://doi.org/10.3390/nano8020067
Wang Y, Wong JF, Teng X, Lin XZ, Yang H (2003) “Pulling” nanoparticles into water: phase transfer of oleic acid stabilized monodisperse nanoparticles into aqueous solutions of α-cyclodextrin. Nano Lett 3:1555–1559. https://doi.org/10.1021/nl034731j
Wang T, Zhang C, Liang XJ, Liang W, Wu Y (2011) Hydroxypropyl-β-cyclodextrin copolymers and their nanoparticles as doxorubicin delivery system. J Pharm Sci 100:1067–1079. https://doi.org/10.1002/jps.22352
Wang X, Chen C, Huo D, Qian H, Ding Y, Hu Y, Jiang X (2012) Synthesis of β-cyclodextrin modified chitosan-poly(acrylic acid) nanoparticles and use as drug carriers. Carbohydr Polym 90:361–369. https://doi.org/10.1016/j.carbpol.2012.05.052
Wang Y, Li H, Jin Q, Ji J (2016a) Intracellular host-guest assembly of gold nanoparticles triggered by glutathione. Chem Commun 52:582–585. https://doi.org/10.1039/c5cc07195j
Wang D, Wang T, Xu Z, Yu H, Feng B, Zhang J, Guo C, Yin Q, Zhang Z, Li Y (2016b) Cooperative treatment of metastatic breast cancer using host-guest nanoplatform coloaded with docetaxel and siRNA. Small 12:488–498. https://doi.org/10.1002/smll.201502913
Wang X, Gao Z, Zhang L, Wang H, Hu X (2018, 2018) A magnetic and pH-sensitive composite nanoparticle for drug delivery. J Nanomater. https://doi.org/10.1155/2018/1506342
Weiss G, Yen Y, Neidhart J, Young CS, Weiss S, Ryan J (2011) Abstract 1306: a phase 1b/2a study of CRLX101, a novel nanopharmaceutical of camptothecin, in solid tumor cancer patients who have failed standard therapy. Cancer Res 71:1306–1306. https://doi.org/10.1158/1538-7445.am2011-1306
Xia HB, Yi J, Foo PS, Liu B (2007) Facile fabrication of water-soluble magnetic nanoparticles and their spherical aggregates. Chem Mater 19:4087–4091. https://doi.org/10.1021/cm070918q
Xu Z, Liu S, Liu H, Yang C, Kang Y, Wang M (2015) Unimolecular micelles of amphiphilic cyclodextrin-core star-like block copolymers for anticancer drug delivery. Chem Commun 51:15768–15777. https://doi.org/10.1039/c5cc02743h
Ye Z, Zhang Q, Wang S, Bharate P, Varela-Aramburu S, Lu M, Seeberger PH, Yin J (2016) Tumor-targeted drug delivery with mannose-functionalized nanoparticles self-assembled from amphiphilic β-cyclodextrins. Chem Eur J 22:15216–15221. https://doi.org/10.1002/chem.201603294
Yuan Z, Ye Y, Gao F, Yuan HH, Lan M, Lou K, Wang W (2013) Chitosan-graft-β-cyclodextrin nanoparticles as a carrier for controlled drug release. Int J Pharm 446:191–198. https://doi.org/10.1016/j.ijpharm.2013.02.024
Zafar N, Fessi H, Elaissari A (2013) Cyclodextrin containing biodegradable particles: from preparation to drug delivery applications. Int J Pharm 461:351–366. https://doi.org/10.1016/j.ijpharm.2013.12.004
Zhai Z, Zhang F, Chen X, Zhong J, Liu G, Tian Y, Huang Q (2017) Uptake of silver nanoparticles by DHA-treated cancer cells examined by surface-enhanced Raman spectroscopy in a microfluidic chip. Lab Chip 17:1306–1313. https://doi.org/10.1039/c7lc00053g
Zhang J, Ma PX (2009) Polymeric core-shell assemblies mediated by host-guest interactions: versatile nanocarriers for drug delivery. Angew Chem Int Ed 48:964–968. https://doi.org/10.1002/anie.200804135
Zhang J, Ma PX (2013) Cyclodextrin-based supramolecular systems for drug delivery: recent progress and future perspective. Adv Drug Deliv Rev 65:1215–1233. https://doi.org/10.1016/j.addr.2013.05.001
Zhang X, Wu Z, Gao X, Shu S, Zhang H, Wang Z, Li C (2009) Chitosan bearing pendant cyclodextrin as a carrier for controlled protein release. Carbohydr Polym 77:394–401. https://doi.org/10.1016/j.carbpol.2009.01.018
Zhang N, Li JJ, Jiang W, Ren C, Li JJ, Xin J, Li K (2010) Effective protection and controlled release of insulin by cationic β-cyclodextrin polymers from alginate/chitosan nanoparticles. Int J Pharm 393:213–219. https://doi.org/10.1016/j.ijpharm.2010.04.006
Zhang X, Zheng X, Wu Z, Gao X, Shu S, Wang Z, Li C (2011) β-Cyclodextrin grafting hyperbranched polyglycerols as carriers for nasal insulin delivery. Carbohydr Polym 84:1419–1425. https://doi.org/10.1016/j.carbpol.2011.01.057
Zokaei E, Badoei-dalfrad A, Ansari M (2019) Therapeutic potential of DNAzyme loaded on chitosan/cyclodextrin nanoparticle to recovery of chemosensitivity in the MCF-7 cell line. Appl Biochem Biotechnol 187:708. https://doi.org/10.1007/s12010-018-2836-x
Zuckerman JE, Gritli I, Tolcher A, Heidel JD, Lim D, Morgan R, Chmielowski B, Ribas A, Davis ME, Yen Y (2014) Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. Proc Natl Acad Sci U S A 111:11449–11454. https://doi.org/10.1073/pnas.1411393111
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Pandey, A. (2020). Role of Cyclodextrins in Nanoparticle-Based Systems for Drug Delivery. In: Crini, G., Fourmentin, S., Lichtfouse, E. (eds) The History of Cyclodextrins. Environmental Chemistry for a Sustainable World, vol 52. Springer, Cham. https://doi.org/10.1007/978-3-030-49308-0_7
Download citation
DOI: https://doi.org/10.1007/978-3-030-49308-0_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-49307-3
Online ISBN: 978-3-030-49308-0
eBook Packages: Earth and Environmental ScienceEarth and Environmental Science (R0)